ArsenalBio, a San Francisco, CA-based clinical stage programmable cell therapy company, raised $325M in Series C funding.
The round was led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, Luma Group, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital, among others, with participation from existing investors the Parker Institute for Cancer Immunotherapy (PICI), SoftBank Vision Fund 2, Bristol-Myers Squibb Company, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures.
The company intends to use the funds to advance its lead programs to build its pipeline of therapeutic candidates for solid tumor cancers based on its proprietary T cell engineering technology, including logic gating and drive further innovation in developing tools and processes for identifying new candidate cell therapies.
Led by CEO Ken Drazan, M.D., Arsenal Biosciences is a clinical stage programmable cell therapy company focusing on discovering and developing a pipeline of autologous T cell therapies to defeat cancer. Its full-stack R&D engine is designed to generate multifunctional T cell medicines, enabled by precise and specific CRISPR-mediated insertion of large synthetic DNA cassettes. The company is aiming to build a large DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions.
FinSMEs
04/09/2024